REKINDLE: Your Ability to Cope With a Life-Changing Medical Diagnosis
Quality of Life
Study for those experiencing mental health struggles due to a diagnosis of cancer or other medical illness
Clinicaltrials.gov identifier:NCT07002034
Study Contact Information:
Name: Mark Pollack, Chief Medical Officer
Phone Number: 1-888-880-REUN
Email: [email protected]
About the Study
The REKINDLE Study is testing an investigational single-dose, short-acting psychedelic medication. Our goal is to see if it can help promote better mental health in people with symptoms of depression and anxiety linked to adjustment disorder due to a serious medical diagnosis.
The moment you receive a cancer or similar diagnosis, time can seem to stand still. Profound feelings of fear, anger, and loss are very common. The emotional toll of facing uncertainty, grappling with loss of control, and preparing for difficult changes can be just as heavy as the physical symptoms. It is important to remember to prioritize your mental health in these situations because these feelings can sometimes become truly overwhelming. When these feelings affect your ability to cope, this is called adjustment disorder.
The study drug is an investigational psychedelic medication that is structurally similar to psilocybin (the active compound in “magic mushrooms”) that may help ease psychiatric symptoms of adjustment disorder.
This Study is Open To:
To be eligible to participate, you must be:
- Between 18 and 80 years old
- Diagnosed with cancer (stages 1-4) or other serious conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD), or idiopathic pulmonary fibrosis (IPF)
- Experiencing symptoms of depression and/or anxiety and feeling overwhelmed for at least four weeks
This Study is NOT Open To:
You are not eligible to participate if you:
- Are not between 18 and 80 years old
- Do not have a diagnoses of cancer (stages 1-4) or other serious conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD), or idiopathic pulmonary fibrosis (IPF)
- Are not experiencing symptoms of depression and/or anxiety and feeling overwhelmed for at least four weeks
What the Study Involves
Interested potential study participants will be screened at a study center where they will be assessed to ensure they can participate safely. During the screening process, participants will also meet and get to know their Session Monitors, professionals trained to guide and stay with them during their psychedelic experience.
Participants will receive a single dose of the study medication or a low-dose comparator at the study center and will be monitored in a comfortable environment. Participants will have a 50/50 chance of being assigned to either group (like the flip of a coin). Participants will then be followed for six weeks to evaluate their symptoms and check on their safety.
Including the screening period, dosing visit and the follow-up period, participation in this study will last up to ten weeks.
- The screening period is up to 28 days
- The dosing visit is one day
- The follow-up period is 42 days
There is no charge to participate. Participants may be reimbursed for study-related expenses. Please ask the study staff for details.
To learn more, visit rekindlestudies.com.
Study Contact Information:
Name: Mark Pollack, Chief Medical Officer
Phone Number: 1-888-880-REUN
Email: [email protected]
Locations:
Alabama
City: Birmingham RECRUITING
Facility: UAB, Psychiatry and Behavioral Neurology
Contact Info:
[email protected]
205-996-1198
Arizona
City: Tucson RECRUITING
Facility: University of Arizona
Contact Info:
[email protected]
(520) 626-4804
California
City: San Diego RECRUITING
Facility: Kadima Neuropsychiatry Institute
Contact Info:
[email protected]
858-775-2053
City: Santa Rosa RECRUITING
Facility: Providence Medical Foundation
Contact Info:
[email protected]
Colorado
City: Aurora RECRUITING
Facility: University of Colorado
Contact Info:
[email protected]
Florida
City: Tampa RECRUITING
Facility: University of South Florida, Department of Psychiatry and Behavioral Neuroscience
Contact Info:
[email protected]
813-974-2832
Georgia
City: Atlanta RECRUITING
Facility: Emory University
Contact Info:
[email protected]
404-778-6663
Hawaii
City: Honolulu RECRUITING
Facility: Hawaii Pacific Neuroscience
Contact Info:
[email protected]
Illinois
City: Chicago RECRUITING
Facility: Rush University Medical Center
Contact Info:
[email protected]
Kansas
City: Kansas City RECRUITING
Facility: The University of Kansas Medical Center
Contact Info:
[email protected]
Louisiana
City: Shreveport RECRUITING
Facility: LSU Health Shreveport
Contact Info:
[email protected]
318-675-7064
Massachusetts
City: Boston RECRUITING
Facility: Dana Farber Cancer Institute
Contact Info:
[email protected]
Maryland
City: Rockville RECRUITING
Facility: Sunstone Therapies, PC
Contact Info:
[email protected]
City: Towson RECRUITING
Facility: Sheppard Pratt
Contact Info:
[email protected]
Michigan
City: Ann Arbor RECRUITING
Facility: University of Michigan
Contact Info:
[email protected]
City: Novi RECRUITING
Facility: Henry Ford Health
Contact Info:
[email protected]
North Carolina
City: Chapel Hill RECRUITING
Facility: University of North Carolina at Chapel Hill
Contact Info:
[email protected]
Nebraska
City: Omaha RECRUITING
Facility: University of Nebraska Medical Center
Contact Info:
[email protected]
New Mexico
City: Albuquerque RECRUITING
Facility: University of New Mexico, School of Medicine
Contact Info:
[email protected]
New York
City: Buffalo RECRUITING
Facility: Roswell Park Center Institute
Contact Info:
[email protected]
716-845-1300
City: New York RECRUITING
Facility: NYU Langone Health
Contact Info:
[email protected]
Ohio
City: Cleveland RECRUITING
Facility: Cleveland Clinic
Contact Info:
[email protected]
216-425-7426
City: Columbus RECRUITING
Facility: The Ohio State University, Department of Psychiatry
Contact Info:
[email protected]
Pennsylvania
City: Philadelphia RECRUITING
Facility: University of Pennsylvania
Contact Info:
[email protected]
215-746-6419
Tennessee
City: Knoxville RECRUITING
Facility: Alliance for Multispecialty Research Clinical
Contact Info:
[email protected]
865-659-0406
Texas
City: Austin RECRUITING
Facility: Dell Medical School, University of Texas at Austin
Contact Info:
[email protected]
561-777-5684
Utah
City: Draper RECRUITING
Facility: Cedar Clinical Research Inc.
Contact Info:
[email protected]
Virginia
City: Charlottesville RECRUITING
Facility: UVA Center for Psychiatric Clinical Research
Contact Info:
[email protected]
Washington
City: Seattle RECRUITING
Facility: Seattle Neuropsychiatric Treatment Center
Contact Info:
[email protected]
Wisconsin
City: Madison RECRUITING
Facility: University of Wisconsin at Madison
Contact Info:
[email protected]
Quality of Life
Study for those experiencing mental health struggles due to a diagnosis of cancer or other medical illness
Clinicaltrials.gov identifier:NCT07002034
Study Contact Information:
Name: Mark Pollack, Chief Medical Officer
Phone Number: 1-888-880-REUN
Email: [email protected]